Aldeyra Therapeutics (ALDX) Asset Writedowns and Impairment (2025)
Aldeyra Therapeutics (ALDX) posted Asset Writedowns and Impairment of $267261.0 for Q1 2025.
Aldeyra Therapeutics (ALDX) Asset Writedowns and Impairment (2025) Analysis & Trends
Aldeyra Therapeutics' Asset Writedowns and Impairment history runs 1 years deep, the most recent figure standing at $267261.0 for Q1 2025.
- Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $267261.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $267261.0 (changed N/A YoY) and the FY2025 annual result came in at $267261.0, changed N/A from the prior year.
- Asset Writedowns and Impairment was $267261.0 for Q1 2025 at Aldeyra Therapeutics.
- Across five years, Asset Writedowns and Impairment topped out at $267261.0 in Q1 2025 and bottomed at $267261.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | Aldeyra Therapeutics | 95.35 Mn | 95.35 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 267,261.00 |
| Mar 31, 2025 | 267,261.00 |